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Diagnostic workup of metastatic head and neck squamous cell carcinoma of unknown primary site has traditionally included
CT and/or MRI imaging and endoscopic biopsies. Routine bilateral tonsillectomy is highly controversial and the role of PET/CT is
evolving,bothforidentiﬁcationofpotentialprimarysitesandthedetectionofdistantmetastases.Wereportacaseofcervicalnodal
metastasis of squamous cell carcinoma from an unknown primary site, in which dual-modality PET/CT led to the unexpected
diagnosis of synchronous bilateral tonsillar cancers. In addition, PET/CT correctly distinguished pulmonary sarcoidosis from
metastatic disease in this patient.
1.Introduction
The standard workup for a head and neck squamous cell car-
cinoma of unknown primary site (CUPS) includes physical
exam,chestimaging,CTorMRIoftheheadandneckregion,
and panendoscopy with biopsies of potential primary sites.
Given that a high proportion of occult tumors are located
in the palatine tonsils, diagnostic unilateral tonsillectomy is
frequently recommended. Bilateral tonsillectomy has been
proposed but remains controversial. This case illustrates that
skilled interpretation of PET/CT, incorporating a diagnostic-
quality anatomic imaging component, can correctly identify
clinically inapparent synchronous tonsil cancers and assist in
the evaluation for distant disease.
2.CaseReport
A 57-year-old man presented with a ﬂu-like syndrome and
right neck swelling. Fine-needle aspiration of the right neck
mass revealed squamous cell carcinoma, and a CT scan of
the head and neck revealed an enlarged right jugulodigastric
lymph node (2.9 × 2.5cm). A CT scan of the chest showed
mediastinal and bilateral hilar lymphadenopathy with bilat-
eral interstitial nodular opacities in the upper lobes. A
diagnosticPETscanshowedtherightjugulodigastricnodeto
haveastandardizeduptakevalue(SUV)of5.98withbilateral
oropharyngeal radiotracer activity. Surprisingly, radiotracer
uptake in the oropharynx was higher in the left tonsil
compared to the right. The patient underwent two rounds
of panendoscopy with biopsies which revealed, respectively,
mild dysplasia of the right tonsil and a friable and nodular
inferior border of the right tonsil containing carcinoma
in situ. Diagnostic right tonsillectomy showed extensive
squamous cell carcinoma in situ with a high suspicion of
invasion. The left tonsil was speciﬁcally noted to be clinically
unremarkable.
A repeat PET/CT was performed for the purposes of
radiotherapyplanningandthisstudyconﬁrmedthepresence2 International Journal of Otolaryngology
Figure 1: Axial view from fused PET/CT study demonstrates an
enlarged right jugulodigastric node with heterogeneous but overall
increased FDG avidity with peak SUV of 7.3.
of a 3cm right neck level II lymph node with an SUV
of 7.3, with central necrosis (Figure 1). A diagnostic head
and neck contrast-enhanced CT was included as part of the
PET/CT study, as is our institutional practice and review
of the CT elicited concern for extracapsular spread. FDG-
avidity was again noted bilaterally in the oropharynx, with
the intact left tonsil showing a maximum SUV of 8.7 as
compared to maximum SUV of 6.6 in the tonsillar bed
on the right (Figure 2(a)). However, the left tonsil was
noted to be unusually bulky and irregular on the CT
portion of the imaging study (Figure 2(b)). The PET/CT
also demonstrated mild, symmetric FDG avidity in the
mediastinal and hilar regions, which was considered more
consistent with an inﬂammatory rather than neoplastic
process, given the low FDG uptake (Figure 3). High-
resolution chest CT also suggested sarcoidosis. Due to the
possibility that the asymmetric uptake and enlargement of
the intact left tonsil might have been caused by the recent
right tonsillectomy, the patient underwent a diagnostic left
tonsillectomy. While the appearance of the left tonsil was
still normal on examination, pathologic analysis revealed
extensive in situ and invasive squamous cell carcinoma
(Figure 4(a)). Immunohistochemical staining for p16 was
diﬀusely and strongly positive (Figure 4(b)). Concurrent
cisplatin was recommended due to the radiographically
identiﬁed extracapsular extension, but the patient chose
cetuximab in conjunction with intensity-modulated radio-
therapy. Radiation treatment targeted the bilateral tonsillar
beds and the right neck lymph node. The prescription dose
was 6996cGy, delivered over 33 fractions of treatment, with
weekly localization using conebeam CT imaging to position
the patient on the radiation therapy table. The concurrent
cetuximab was delivered over 8 weekly infusion cycles and
was well tolerated, with development of a moderate skin rash
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Figure 2: (a) Coronal FDG PET showing bilateral but asymmetric
tonsillar FDG avidity. The patient had undergone diagnostic right
tonsillectomypriortothisPET/CTstudy.However,peakSUVinthe
contralateralleftpalatinetonsilmeasured8.7.(b)AxialCTshowing
pronounced left-sided tonsillar enlargement corresponding to the
high FDG avidity.
as is typical for this class of targeted therapy. After 2 years
of followup, the patient is well with no evidence of recurrent
cancer and his sarcoidosis remains stable.
3. Discussion
The exact diagnostic workup for CUPS remains a matter
of debate. Examination under anesthesia is mandatory, but
biopsy procedures are variable. Because a signiﬁcant per-
centage of CUPS arise from the palatine tonsil [1–4], a
typical recommendation is that an ipsilateral tonsillectomy
be included in the standard workup [2, 3, 5–7]. However, aInternational Journal of Otolaryngology 3
Figure 3: Coronal FDG-PET shows mild mediastinal and bilateral
hilar FDG uptake, which is nonspeciﬁc but consistent with
sarcoidosis.
case series published by Koch et al. [8] found that the inci-
dence of bilateral tonsillar cancers approaches 10%, lead-
ing to a recommendation for routine diagnostic bilateral
tonsillectomy based on the goals of early control of all
primary disease [5], avoidance of radiation to healthy tissues
[3, 6], improved surveillance ability [6], and improved
overall success rates [9, 10] .Y e td e s p i t ep r o b a b l eb e n e ﬁ t
in a select number of patients, the practice of bilateral
tonsillectomy remains controversial.
The optimal imaging workup likewise remains unde-
ﬁned. A retrospective review found that PET/CT was supe-
rior to CT, MRI or whole body PET in primary site detection
[9]. Compared to CT alone, PET/CT has higher sensitivity
[4, 11], higher negative predictive value [4], and comparable
[11] or inferior speciﬁcity [4] in the investigation of head
and neck CUPS. Studies have estimated that the sensitivity
of PET/CT may range from 66–87.5% with a speciﬁcity of
70–92.9% [4, 11–13]. A positive predictive value of 88.8%
has been reported [12].
A retrospective review by Cianchetti et al. [7] included
a proposed diagnostic algorithm for CUPS of the head and
neck, including a complete physical exam, CT and/or MRI,
panendoscopy with biopsies, PET/CT based on “indetermi-
nate ﬁndings,” and unilateral or bilateral tonsillectomy in
patients with extant lymphoid tissue [7]. In contrast, some
authors have advocated for upfront PET/CT in order to
direct the choice of biopsy sites at the time of panendoscopy,
thereby increasing accuracy in detecting singular or syn-
chronous primary cancers [14, 15]. We agree with the latter
recommendation.
Of note, this patient was a lifelong nonsmoker and show-
ed strong immunohistochemical staining for p16, consist-
ent with association with high-risk human papillomavirus
infection [16]. HPV-related oropharyngeal cancers treated
with chemoradiation carry a superior prognosis, which is
retained despite traditional indicators of aggressiveness such
as regional nodal metastasis [17, 18]. One report did not
ﬁnd an increased propensity for bilateral tonsillar cancer in
specimens that were positive for p16 immunohistochemistry
and HPV-16 in situ hybridization [19]. However, other re-
ports have speculated on the possibility of HPV-related ﬁeld
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Figure 4: (a) Hematoxylin and eosin stained section of the left
tonsil showing invasive squamous cell carcinoma, magniﬁcation
100X (b) Immunohistochemical stain for p16 performed on a serial
section, magniﬁcation 100X.
cancerization in Waldeyer’s ring [20] or an HPV-related pre-
disposition to the development of bilateral disease spread
[21].
Finally, PET/CT ﬁndings may result in changes to staging
or alteration of radiation therapy target volumes [13, 22–24].
A large prospective, blinded study speciﬁcally noted changes
to the gross tumor volume, the extent of regional disease,
the prescribed dose of radiation and/or the selection of
treatment modality, leading to nearly a third of the patients’
management being signiﬁcantly altered [22]. One study
found higher control rates and favorable toxicity proﬁles
when utilizing PET/CT to guide radiotherapy [25].
Oncologists should be aware of the limitations of
PET/CT in cases of head and neck CUPS. A high rate of
false positive ﬁndings with PET/CT in the postoperative and
preradiotherapy period has been shown [26]. Conditions
such as infection, healing, or localized inﬂammatory pro-
cesses as well as foreign bodies (catheters, prostheses) have
beenshowntoproducefalsepositiveresultsonPET/CT[27].
Though rare, the so-called “sarcoid-like reaction to malig-
nancy” should be considered when interpreting PET/CT
[28]. F-18 ﬂuorothymidine may have an advantage over4 International Journal of Otolaryngology
F-18 ﬂuorodeoxyglucose PET/CT scans for distinguishing
sarcoidosis from malignancy [29].
Most importantly, the value of obtaining imaging studies
of appropriate quality and technique should not be under-
stated. While PET alone may be adequate for CUPS workup
[30], other studies have found higher rates of sensitivity
for PET/CT in identifying the primary site (up to 67%)
as compared to historical rates reported from PET alone
[31, 32], or with either PET or CT alone [33]. In the latter
study, the imaging was interpreted by a team comprised of a
nuclear medicine physicianand a diagnostic radiologist [33].
Given the major changes in staging and therapy that result
from identiﬁcation of one or more head and neck primary
sites, at our institution we recommend a dual-modality
fused PET/CT including a diagnostic-quality head and neck
contrast-enhancedCT,aspartofthestandardCUPSworkup,
ideally obtained prior to endoscopy and directed biopsies
and/or bilateral tonsillectomy. We recommend evaluation by
both a nuclear medicine and neuroradiology specialist to
maximize the interpretative yield.
4. Conclusions
Skilled anatomic interpretation of PET/CT imaging led to
the correct diagnosis of bilateral synchronous tonsillar squa-
mous cell carcinoma. This case illustrates the expanding ap-
plications of PET/CT for head and neck cancer including
the identiﬁcation of occult or synchronous primaries in
CUPS, detection of metastasis, and radiotherapy target
identiﬁcation. A properly executed PET/CT can greatly assist
in the initial workup of patients with head and neck CUPS.
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